AR227521A1 - Procedimiento para la preparacion de derivados de 3,5-diamino-6-(fenil substituido)-1,2,4-triazinas e intermediario para realizar el procedimiento - Google Patents

Procedimiento para la preparacion de derivados de 3,5-diamino-6-(fenil substituido)-1,2,4-triazinas e intermediario para realizar el procedimiento

Info

Publication number
AR227521A1
AR227521A1 AR281263A AR28126380A AR227521A1 AR 227521 A1 AR227521 A1 AR 227521A1 AR 281263 A AR281263 A AR 281263A AR 28126380 A AR28126380 A AR 28126380A AR 227521 A1 AR227521 A1 AR 227521A1
Authority
AR
Argentina
Prior art keywords
procedure
triazines
intermediary
diamine
derivatives
Prior art date
Application number
AR281263A
Other languages
English (en)
Spanish (es)
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10505597&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR227521(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Application granted granted Critical
Publication of AR227521A1 publication Critical patent/AR227521A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075—Two hetero atoms, in positions 3 and 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/16—Compounds containing any of the groups, e.g. aminoguanidine
    • C07C281/18—Compounds containing any of the groups, e.g. aminoguanidine the other nitrogen atom being further doubly-bound to a carbon atom, e.g. guanylhydrazones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/15—Preparation of carboxylic acids or their salts, halides or anhydrides by reaction of organic compounds with carbon dioxide, e.g. Kolbe-Schmitt synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/347—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups
    • C07C51/363—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups by introduction of halogen; by substitution of halogen atoms by other halogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
AR281263A 1979-06-01 1980-05-30 Procedimiento para la preparacion de derivados de 3,5-diamino-6-(fenil substituido)-1,2,4-triazinas e intermediario para realizar el procedimiento AR227521A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB7919257 1979-06-01

Publications (1)

Publication Number Publication Date
AR227521A1 true AR227521A1 (es) 1982-11-15

Family

ID=10505597

Family Applications (1)

Application Number Title Priority Date Filing Date
AR281263A AR227521A1 (es) 1979-06-01 1980-05-30 Procedimiento para la preparacion de derivados de 3,5-diamino-6-(fenil substituido)-1,2,4-triazinas e intermediario para realizar el procedimiento

Country Status (30)

Country Link
US (2) US4486354A (de)
EP (2) EP0059987B1 (de)
JP (2) JPS5625169A (de)
AR (1) AR227521A1 (de)
AT (1) AT370097B (de)
AU (2) AU530999B2 (de)
BG (1) BG60427B2 (de)
CA (1) CA1112643A (de)
CS (1) CS234018B2 (de)
CZ (1) CZ384891A3 (de)
DD (1) DD151309A5 (de)
DK (1) DK153787C (de)
ES (1) ES8104993A1 (de)
FI (1) FI67844C (de)
GE (1) GEP19960470B (de)
GR (1) GR68380B (de)
HU (1) HU182086B (de)
IE (1) IE49823B1 (de)
IL (1) IL60201A (de)
IT (1) IT1147087B (de)
MX (1) MX9202962A (de)
MY (1) MY8500062A (de)
NL (1) NL950007I2 (de)
NZ (1) NZ193890A (de)
PL (1) PL124029B1 (de)
SU (1) SU1055331A3 (de)
UA (1) UA5576A1 (de)
YU (1) YU145680A (de)
ZA (1) ZA803250B (de)
ZW (1) ZW12980A1 (de)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0086502B1 (de) * 1979-08-16 1987-03-25 The Wellcome Foundation Limited Substituierte aromatische Triazine
GB8328757D0 (en) * 1983-10-27 1983-11-30 Wellcome Found Chemical compounds
DE3600891A1 (de) * 1986-01-15 1987-07-16 Bayer Ag 1,8-verbrueckte 4-chinolon-3-carbonsaeuren und diese enthaltende arzneimittel
GB8613183D0 (en) * 1986-05-30 1986-07-02 Wellcome Found Triazine salt
US4972496A (en) * 1986-07-25 1990-11-20 Grid Systems Corporation Handwritten keyboardless entry computer system
FI895821A0 (fi) * 1988-12-07 1989-12-05 Wellcome Found Farmaceutiskt aktiva cns foereningar.
US5136080A (en) * 1989-12-04 1992-08-04 Burroughs Wellcome Co. Nitrile compounds
GB9012311D0 (en) * 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
GB9012312D0 (en) * 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
GB2257363B (en) * 1991-01-30 1994-09-28 Wellcome Found Water dispersible tablets containing acyclovir
GB9124807D0 (en) * 1991-11-22 1992-01-15 Wellcome Found Pharmaceutical formulations
US5629016A (en) * 1991-01-30 1997-05-13 Glaxo Wellcome Inc. Water-dispersible tablets
GB9203483D0 (en) * 1992-02-19 1992-04-08 Wellcome Found Anti-inflammatory compounds
WO1993025207A1 (en) * 1992-06-12 1993-12-23 The Wellcome Foundation Limited Use of 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine isethionate for the treatment and prevention of dependence, tolerance and sensitization of drugs
GB9215908D0 (en) * 1992-07-27 1992-09-09 Wellcome Found Water dispersible tablets
FR2699077B1 (fr) * 1992-12-16 1995-01-13 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.
US6133299A (en) * 1993-02-25 2000-10-17 Warner-Lambert Company Methods for treating neurodegenerative diseases and disorders using N-(2,6-disubstituted aromatic)-N'-pyridinyl ureas and other anticonvulsant compounds
US5866597A (en) * 1993-03-19 1999-02-02 Glaxo Wellcome Inc. Use of triazine compounds for the treatment of memory and learning disorders
GB9305693D0 (en) * 1993-03-19 1993-05-05 Wellcome Found Therapeutic triazine compounds and use
GB9305692D0 (en) * 1993-03-19 1993-05-05 Wellcome Found Therapeutic triazine compounds and use
US5698226A (en) * 1993-07-13 1997-12-16 Glaxo Wellcome Inc. Water-dispersible tablets
GB9317146D0 (en) * 1993-08-18 1993-10-06 Wellcome Found Therapeutic combinations
GB9424766D0 (en) * 1994-12-07 1995-02-08 Wellcome Found Pharmaceutical composition
WO1996020934A1 (en) * 1994-12-30 1996-07-11 The Wellcome Foundation Limited Process for the preparation of lamotrigine
GB9426448D0 (en) * 1994-12-30 1995-03-01 Wellcome Found Process
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation
GB9518027D0 (en) * 1995-09-05 1995-11-08 Wellcome Found Pharmacologically active compound
FR2741879A1 (fr) * 1995-12-05 1997-06-06 Esteve Labor Dr Derives de fluorophenyl-triazines et pyrimidines, leur preparation et leur application en tant que medicament
US6202491B1 (en) 1997-07-22 2001-03-20 Skf Condition Monitoring, Inc. Digital vibration coupling stud
GB9726987D0 (en) * 1997-12-22 1998-02-18 Glaxo Group Ltd Compounds
US6124500A (en) * 1998-03-09 2000-09-26 Rohm And Haas Company Process for synthesizing benzoic acids
GB9812413D0 (en) 1998-06-10 1998-08-05 Glaxo Group Ltd Compound and its use
CA2334937C (en) * 1998-12-14 2004-09-21 Torrent Pharmaceuticals Ltd. An improved process for the preparation of 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
US20020055177A1 (en) * 1999-03-10 2002-05-09 Glaxo Wellcome Inc. Compound and its use
GB9907965D0 (en) * 1999-04-09 1999-06-02 Glaxo Group Ltd Medical use
EP1169060B1 (de) * 1999-04-09 2005-08-31 Euro-Celtique S.A. Natrium kanalblocker zusammensetzungen und deren verwendung
AU763244B2 (en) * 2000-01-03 2003-07-17 Rpg Life Sciences Limited A process for the preparation of 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine, commonly known as lamotrigine
IL134730A (en) * 2000-02-25 2003-10-31 Chemagis Ltd Process for preparing substituted benzoyl cyanide amidinohydrazones
PL365378A1 (en) 2000-11-30 2005-01-10 Pfizer Products Inc. Combination of gaba agonists and aldose reductase inhibitors
PT1337271E (pt) 2000-11-30 2005-01-31 Pfizer Prod Inc Combinacao de agonistas de gaba e inibidores de sorbitol desidrogenase
WO2002068398A1 (en) * 2001-02-27 2002-09-06 Teva Pharmaceutical Industries Ltd. New crystal forms of lamotrigine and processes for their preparations
PT1423168E (pt) * 2001-09-03 2006-05-31 Newron Pharm Spa Composicao farmaceutica que compreende gabapentina ou um seu analogo e uma x-aminoamida e a sua utilizacao como analgesico
CA2366521C (en) 2001-12-24 2007-03-06 Brantford Chemicals Inc. A new and efficient process for the preparation of lamotrigine and related 3,5-diamino-6-substituted-1,2,4-triazines
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
WO2003090693A2 (en) * 2002-04-23 2003-11-06 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing lamotrigine particles of defined morphology
US8637512B2 (en) 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
HU225667B1 (en) 2002-09-20 2007-05-29 Richter Gedeon Nyrt Method for producing high-purity 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
ES2209639B1 (es) 2002-10-31 2005-08-01 Vita Cientifica, S.L. Procedimiento para la obtencion de un compuesto farmaceuticamente activo y obtencion de su intermedio.
EP1603889A1 (de) * 2003-03-17 2005-12-14 Hetero Drugs Limited Neue kristalline formen von lamotrigin
US7504516B2 (en) 2003-03-27 2009-03-17 Hetero Drugs Limited Crystalline forms of candesartan cilexetil
MXPA05012317A (es) 2003-05-16 2006-01-30 Pfizer Prod Inc Combinaciones terapeuticas de agentes antipsicoticos atipicos con agentes moduladores del gaba anticonvulsivos o benzodiazepinas.
WO2004103340A1 (en) * 2003-05-20 2004-12-02 Ranbaxy Laboratories Limited Water dispersible tablets of lamotrigine
GB2395483A (en) * 2003-07-03 2004-05-26 Jubilant Organosys Ltd Crystalline lamotrigine and its monohydrate
EP1691811B1 (de) 2003-12-11 2014-07-23 Sunovion Pharmaceuticals Inc. Kombination aus einem sedativum und einem neurotransmitter-modulator und verfahren zur verbesserung der schlafqualität und zur behandlung von depression
JP2007537151A (ja) * 2004-01-29 2007-12-20 ファイザー・プロダクツ・インク γ−アミノ酪酸モジュレータと５−ＨＴ１Ｂ受容体アンタゴニストとの組合せ
EP1737473A4 (de) * 2004-04-19 2009-08-26 Noven Therapeutics Llc Lithium-kombinationen und relevante verwendungen
KR101277520B1 (ko) * 2004-09-10 2013-06-21 뉴론 파마슈티칼즈 에스. 피. 에이. （할로벤질옥시）벤질아미노－프로판아미드를 포함하는 선택적 나트륨 및／또는 칼슘 채널 조절제로서 유용한 약제학적 조성물
US7825151B2 (en) * 2005-09-23 2010-11-02 Janssen Pharmaceutica Nv Hexahydro-cyclooctyl pyrazole cannabinoid modulators
US20070123578A1 (en) * 2005-09-23 2007-05-31 Fina Liotta Hexahydro-cycloheptapyrazole cannabinoid modulators
US8378117B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
US8378096B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
BRPI0616263A2 (pt) 2005-09-23 2011-06-14 Janssen Pharmaceutica Nv moduladores canabinàides do tipo tetrahidro-ciclopentil pirazol
UA93389C2 (en) * 2005-09-23 2011-02-10 Янссен Фармацевтика H.B. Hexahydro cyclooctyl pyrazole cannabinoid modulators
US20070117858A1 (en) * 2005-11-23 2007-05-24 Mingde Xia Substituted 5-heteroaryl-1-phenyl-pyrazole cannabinoid modulators
US7526911B2 (en) * 2006-02-03 2009-05-05 Rolls-Royce Corporation Gas turbine engine fuel system with fuel metering valve
US7795294B2 (en) * 2006-02-14 2010-09-14 Janssen Pharmaceutica N.V. Tetrahydro-2H-indazole pyrazole cannabinoid modulators
US8012957B2 (en) * 2006-03-27 2011-09-06 Janssen Pharmaceutica Nv Tetrahydro-1H-1,2,6-triaza-azulene cannabinoid modulators
US20070254911A1 (en) * 2006-03-27 2007-11-01 Mingde Xia Tetrahydro-Pyrazolo[3,4-c]Pyridine Cannabinoid Modulators
WO2007122638A2 (en) * 2006-04-26 2007-11-01 Ratnamani Bio-Chemicals & Pharmaceuticals Pvt. Ltd. An improved process for preparation of lamotrigine intermediates
ES2337415T3 (es) * 2006-05-31 2010-04-23 Calaire Chimie Sas Metodo para la preparacion de lamotrigina y su producto intermedio cloruro de 2,3-diclorobenzoilo.
GB0613836D0 (en) * 2006-07-13 2006-08-23 Univ Greenwich New medical use of triazine derivatives
US20120142919A1 (en) 2006-08-02 2012-06-07 Medichem, S.A. Method for synthesizing lamotrigine
CA2659290A1 (en) * 2006-08-14 2008-02-21 Jean-Paul Roduit A process for the preparation of lamotrigine
EP2117538A1 (de) 2007-01-24 2009-11-18 Glaxo Group Limited Pharmazeutische zusammensetzungen mit 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
US7943653B2 (en) * 2007-08-13 2011-05-17 Janssen Pharmaceutica N.V. Substituted 5-vinylphenyl-1-phenyl-pyrazole cannabinoid modulators
US20090076010A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched lamotrigine
US8486927B2 (en) * 2007-11-09 2013-07-16 Thar Pharmaceuticals Crystalline forms of lamotrigine
GB0800741D0 (en) 2008-01-16 2008-02-20 Univ Greenwich Cyclic triazo and diazo sodium channel blockers
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
MX2011012044A (es) 2009-05-13 2011-12-14 Nektar Therapeutics Compuestos de triazina aromatica sustituida que contienen oligomeros.
EP2564836A1 (de) 2009-05-20 2013-03-06 Ranbaxy Laboratories Limited Lamotriginformulierungen mit gesteuerter Freisetzung
GB2471713A (en) 2009-07-08 2011-01-12 Univ Greenwich 1,2,4-triazine derivatives and their use as sodium channel blockers
GB2471729A (en) 2009-07-08 2011-01-12 Univ Greenwich 1,2,4-triazine derivatives and their use as sodium channel blockers
US20110052686A1 (en) 2009-09-03 2011-03-03 Ranbaxy Laboratories Limited Modified release lamotrigine tablets
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
WO2013183985A1 (en) 2012-06-05 2013-12-12 Erasmus University Medical Center Rotterdam Method of treating cognitive impairment and compounds for use therein
US10189859B2 (en) 2013-12-21 2019-01-29 Nektar Therapeutics Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine
US10576086B2 (en) 2015-06-12 2020-03-03 University Of Greenwich Triazine derivatives as interferon-gamma inhibitors
TWI808952B (zh) 2016-12-16 2023-07-21 瑞士商愛杜西亞製藥有限公司 包含t型鈣通道阻斷劑之醫藥組合
TWI826531B (zh) 2018-09-21 2023-12-21 南韓商愛思開生物製藥股份有限公司 具有㗁二唑之化合物及包含該化合物之醫藥組合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB759014A (en) * 1952-02-26 1956-10-10 Wellcome Found Improvements in triazines and their manufacture
AT190941B (de) * 1954-09-22 1957-07-25 Chemie Linz Ag Verfahren zur Herstellung neuer Guanylhydrazone
US2952677A (en) * 1956-10-01 1960-09-13 Ici Ltd Aminoguanadine compounds
BE663481A (de) * 1964-05-05
DE1802364C3 (de) * 1967-10-12 1975-03-20 Shell Internationale Research Maatschappij B.V., Den Haag (Niederlande) Arzneimittel mit thymeretischer Wirkung
GB1223491A (en) * 1967-10-13 1971-02-24 American Home Prod Guanidines
US3637688A (en) * 1970-01-09 1972-01-25 American Home Prod 6-(fluoro and trifluoromethyl phenyl)-3 5-diamino - 1 2 4 - triazines and substituted - 6 - phenylalkyl-3,5-diamino-1 2 4-triazines
EP0086502B1 (de) * 1979-08-16 1987-03-25 The Wellcome Foundation Limited Substituierte aromatische Triazine

Also Published As

Publication number Publication date
ES491998A0 (es) 1981-05-16
EP0021121A1 (de) 1981-01-07
HU182086B (en) 1983-12-28
IL60201A (en) 1984-05-31
AU5890680A (en) 1980-12-04
IT8048848A0 (it) 1980-05-30
IL60201A0 (en) 1980-07-31
UA5576A1 (uk) 1994-12-28
ZW12980A1 (en) 1982-01-06
NL950007I2 (nl) 1997-02-03
ZA803250B (en) 1982-01-27
CS234018B2 (en) 1985-03-14
ES8104993A1 (es) 1981-05-16
EP0059987A1 (de) 1982-09-15
JPS6133163A (ja) 1986-02-17
JPH0144706B2 (de) 1989-09-29
AU530999B2 (en) 1983-08-04
DK233880A (da) 1980-12-02
AU566870B2 (en) 1987-11-05
IE801126L (en) 1980-12-01
EP0021121B1 (de) 1983-05-11
ATA289680A (de) 1982-07-15
EP0059987B1 (de) 1985-08-14
FI801758A (fi) 1980-12-02
GEP19960470B (en) 1996-08-29
AT370097B (de) 1983-02-25
CZ384891A3 (en) 1993-10-13
SU1055331A3 (ru) 1983-11-15
FI67844C (fi) 1985-06-10
JPH0144179B2 (de) 1989-09-26
US4486354A (en) 1984-12-04
NZ193890A (en) 1984-07-06
FI67844B (fi) 1985-02-28
NL950007I1 (nl) 1995-06-16
DK153787B (da) 1988-09-05
MY8500062A (en) 1985-12-31
DD151309A5 (de) 1981-10-14
US4602017A (en) 1986-07-22
MX9202962A (es) 1992-07-01
IE49823B1 (en) 1985-12-25
CA1112643A (en) 1981-11-17
YU145680A (en) 1983-02-28
IT1147087B (it) 1986-11-19
DK153787C (da) 1989-01-16
GR68380B (de) 1981-12-28
PL124029B1 (en) 1982-12-31
PL224633A1 (de) 1981-02-13
BG60427B2 (bg) 1995-03-31
JPS5625169A (en) 1981-03-10

Similar Documents

Publication Publication Date Title
AR227521A1 (es) Procedimiento para la preparacion de derivados de 3,5-diamino-6-(fenil substituido)-1,2,4-triazinas e intermediario para realizar el procedimiento
ES489934A0 (es) Procedimiento para la preparacion de derivados de pipreridi-na
ES490536A0 (es) Procedimiento para la preparacion de derivados de la glici- namida
AR221682A1 (es) Procedimiento para la preparacion de derivados de 2(imidazol-4-il,piridil-2-ilo o tiazolil-2-ilo-butil o metiltio-etilamino)-5-(1-naftil-alquilenoxi;1,3-benzodioxolil-alquilenoxi;1,4-benzodioxinilalquilenoxi;1-naftilalquilen;1,3-benzodioxolilalquilen;o 1,4-benzo dioxinilalquilen)-4-pirimidona o 4-pirimidintiona
AR230059A1 (es) Procedimiento para obtener derivados de piperidil-1-il-alcoxi o hidroxialcoxi-carboestirilo o 3,4-dihidrocarboestirilo
AR229089A1 (es) Procedimiento para la preparacion de derivados de acido 2--(mercaptometil,-etil o-propil)-1,3-dioxo-1h-1,2,4-triazolo(1,2-a)piridazin-5-carboxilico
ES487629A0 (es) Procedimiento para la preparacion de nuevos derivados de alfa-(3,4-diclorofenil)-2-imidazolina-2-metanol y alfa-(3,4-diclorofenil)-1,4,5,6-tetrahidro-2-pirimidinametanol
ES491341A0 (es) Procedimiento para la obtencion de derivados fluorados de triazolil-butano, de efecto fungicida
ES491142A0 (es) Procedimiento para la preparacion de derivados de fenileti- lamina
ES491154A0 (es) Procedimiento para la preparacion de derivados furanonicos
ES497530A0 (es) Procedimiento para la preparacion de derivados de 2,3-indo- lediona
AR225611A1 (es) Procedimiento para la obtencion de nuevos derivados 5-halogen-6-(2',4'-dihalofenoxi)-1(o 3)-sustituido-2h-1,3-dihidrobenzimidazol-2-tiona,o similares
ES491683A0 (es) Procedimiento para la preparacion de 1,3,7-trialquilxantinas
MX6221E (es) Procedimiento para la preparacion de derivados de homoserina
ES501213A0 (es) Procedimiento para la preparacion de derivados de 2,3,4,5- tetrahidro-1-benzoxepin-3,5-diona
AR230994A1 (es) Procedimiento para preparar compuesto de 3'-substituido-5'-(2-amino-4-piridil)-1',2',4'-triazol
AR227436A1 (es) Procedimiento para la preparacion de bases de 3 amino-5-(4-piridil)-1,2,4-triazol
ES491010A0 (es) Procedimiento para la preparacion de derivados 17-beta de 4-diazo-5- alfa-androstan-3-onas
MX5725E (es) Procedimiento para la preparacion de derivados de 5,8-dihidrofuro-(3,2-b)-1,8-naftiridina
AR223434A1 (es) Procedimiento para la preparacion de derivados de i-piperidino-ftalazina
ES489822A0 (es) Procedimiento para la obtencion de 3-sulfonil-benzo-1,2-4- triazinas y benzo-1,2-4-triazin-1-oxidos
ES498612A0 (es) Procedimiento para la fabricacion de 5-amino-1,2,3-tiadiazo-les
ES491342A0 (es) Procedimiento para la obtencion de derivados fluorados de i-imidazolil-butano, de efecto fungicida
ES488694A0 (es) Procedimiento para la preparacion de 5-(2-clorobencil)-4,5,6,7-tetrahidrotieno (3,2,c) piridina
AR230635A1 (es) Procedimiento para obtener derivados de n,n-dimetil(aza-1-biciclo-(2,22)-octil-3)-1 0h-fenotiazinsulfonamida-2